Gene therapy aims to treat disease by introducing genetic material into cells. The approach reaches needs that small molecules and antibodies handle poorly: inherited disorders, cancer, and infectious diseases. It also brings risks of its own: immune reactions, off-target effects, and long-term consequences. Gene therapy therefore requires rigorous safety evaluation before it can be applied to humans.
One of the most important tools for gene therapy safety evaluation is the use of non-human primates (NHPs), such as monkeys and apes. NHPs are closely related to humans in genetics, physiology, immunology, and behavior. They can provide information on the biodistribution, pharmacokinetics (PK), efficacy, and toxicity of gene therapy products that cannot be obtained from other animal models or in vitro studies, and they help predict the potential adverse events and outcomes of gene therapy in humans.
Why NHP Data Cannot Be Replaced
A primate study usually answers a question a rodent cannot. Capsid tropism, the spread of vector genomes across tissues, and the immune response to a capsid or a transgene product differ between species, so a mouse study cannot settle any of them for a primate. That is why NHP work sits after the vector is characterized and before the first human dose.
Delivery route decides what the distribution question is. A vector given systemically is judged on liver and peripheral tissue distribution; a CNS-directed program is judged on levels near the injection site, and studies of that kind often rely on Intrathecal (IT) Injection or direct delivery into the brain. Biodistribution Imaging Service work answers the same question with imaging.
The Constraints On NHP Use
The use of NHPs in gene therapy safety evaluation also raises ethical, scientific, and regulatory issues. NHPs are highly sentient and social animals that deserve respect and protection. They are also scarce and expensive resources that should be used sparingly and efficiently. They are subject to different regulations and guidelines in different countries and regions, which can affect the quality and comparability of the data.
What A Good NHP Gene Therapy Study Includes
For those reasons, practice is built on the following points:
- Selecting the most appropriate NHP species and strain for the gene therapy product and target disease
- Designing the NHP study with adequate sample size, duration, endpoints, and controls
- Conducting the NHP study in accordance with the principles of replacement, reduction, and refinement (3Rs) of animal use
- Applying rigorous standards for animal welfare and ethical review
- Reporting the NHP study results transparently and comprehensively
- Harmonizing the NHP study requirements and expectations across different regulatory authorities
Species and strain selection constrains the rest, because a strain with a documented history in the relevant model gives a reviewer a reference point. Sampling works the same way: points covering the peak of expression, the decline, and the late phase tell a different story from points that cover only the peak.
Three Programs Built On NHP Data
Three programs show what primate data were asked to establish.
- Treatment of Hemophilia B: In a study published in the New England Journal of Medicine in 2011, researchers used gene therapy to treat Hemophilia B in rhesus macaques. The researchers used adeno-associated virus (AAV) to deliver the missing gene to the liver. The treatment corrected the bleeding defect in the primates, and the therapy was subsequently tested and approved for use in humans.
- Treatment of Parkinson's disease: In a study published in the journal Nature in 2017, researchers used gene therapy to treat Parkinson's disease in primates. The researchers used a modified virus to deliver a new gene to the brain cells affected by Parkinson's disease. The gene encodes for a protein that helps produce dopamine, which is essential for controlling movement. The treated primates showed significant improvement in their motor function.
- Treatment of Leber's congenital amaurosis: In a seminal study published in the New England Journal of Medicine in 2008, researchers used gene therapy to treat Leber's congenital amaurosis, a rare inherited form of blindness in children. The researchers used AAV to deliver the correct copy of the disease-causing gene to the affected cells of the retina. The treatment improved the retinal function in the treated non-human primates and subsequently in humans.
What This Means For A Sponsor Program
Effective and responsible NHP use shows up in two places: gene therapy products that reach approval, and scientific knowledge that accumulates alongside better animal welfare.
Prisys Biotech runs NHP Pharmacology studies for advanced therapies, with Toxicology and biodistribution endpoints read from the same protocol. Most programs need three things settled before dosing starts: the vector characterized, the species justified, and the sampling schedule built around the expected expression profile. Animal work runs under the company's animal welfare program, which is reviewed before a protocol is approved.
